Faron Banner Image


  • Ticker FARN
    Exchange LSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Faron Logo Image
  • 11-50 Employees
  • Based in Turku, Finland
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute trauma, cancer growth and spread, and inflammatory diseases. The company's lead product candidates are Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratoryMore distress syndrome (ARDS); and Clevegen, an immunotherapy candidate, designed to prevent tumor growth and metastasis that targets the tumor immune suppressor molecule; and D-ARDS, a diagnostic tool to estimate ARDS severity and to follow ARDS outcome. Faron Pharmaceuticals Oy has a collaboration with MediCity unit of Turku University Medical School. The company was founded in 2003 and is headquartered in Turku, Finland.

Most Recent Annual Report

MOST RECENT 2021 Annual Report

Older/Archived Annual Reports